Assessment of Minimal Residual Disease in Standard-Risk AML. - Wikidata - wikimedia - TriplyDB

Assessment of Minimal Residual Disease in Standard-Risk AML.

Assessment of Minimal Residual Disease in Standard-Risk AML.

http://www.wikidata.org/entity/Q27853325

about

CIViC database Minimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical Applications DNMT3A and TET2 in the Pre-Leukemic Phase of Hematopoietic Disorders Measurable residual disease testing in acute myeloid leukaemia.Current Management of Childhood Acute Myeloid Leukemia.DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling Minimal Residual Disease in Acute Myeloid Leukemia: Still a Work in Progress?Individualizing Therapeutic Strategies in Acute Myeloid Leukemia: Moving Beyond the 'One-Size-Fits-All' Approach.Digital detection of T790M-yes or no to an ultrasensitive assay.Correlation of NPM1 Type A Mutation Burden With Clinical Status and Outcomes in Acute Myeloid Leukemia Patients With Mutated NPM1 Type A.Incorporating measurable ('minimal') residual disease-directed treatment strategies to optimize outcomes in adults with acute myeloid leukemia.Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia Effect of measurable ('minimal') residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia.Ordering of mutations in acute myeloid leukemia with partial tandem duplication of MLL (MLL-PTD).Anti-proliferative activity of the NPM1 interacting natural product avrainvillamide in acute myeloid leukemia.Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.Preleukemia: one name, many meanings.High-throughput sequencing for noninvasive disease detection in hematologic malignancies.Knockdown of miR-128a induces Lin28a expression and reverts myeloid differentiation blockage in acute myeloid leukemia.Molecular and genetic alterations associated with therapy resistance and relapse of acute myeloid leukemia.Frontline treatment of acute myeloid leukemia in adults.Life after transplant: are we becoming high maintenance in AML?Regulation of hematopoietic development by ZBTB transcription factors.Plasma-derived exosomes in acute myeloid leukemia for detection of minimal residual disease: are we ready?Acute myeloid leukemia: 2016 Update on risk-stratification and management.Acute Myeloid Leukemia: How Do We Measure Success?DNMT3A in Leukemia.Minimal Residual Disease in Acute Myeloid Leukemia.Biological and clinical consequences of NPM1 mutations in AML.Spontaneous Remission in an Older Patient with Relapsed FLT3 ITD Mutant AML.Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia.Molecular Mutations and Their Cooccurrences in Cytogenetically Normal Acute Myeloid Leukemia.Approaches for targeting self-renewal pathways in cancer stem cells: implications for hematological treatments.Leukemic stem cells: identification and clinical application.Variable but consistent pattern of Meningioma 1 gene (MN1) expression in different genetic subsets of acute myelogenous leukaemia and its potential use as a marker for minimal residual disease detection.Minimal residual disease in acute myelogenous leukemia.Enhancing acute myeloid leukemia therapy - monitoring response using residual disease testing as a guide to therapeutic decision-making.Acute myeloid leukaemia genomics.Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio.Prognostic Significance of Residual Acute Myeloid Leukemia in Bone Marrow Samples Taken Prior to Allogeneic Hematopoietic Cell Transplantation.

P2860

c905705bf02a7e932360f9bc611be4aec919be78

P248

Q27612411-A5C6F802-4B7A-4B63-A14B-C5765A64397B Q28073464-EC0A7398-7E89-47FC-9656-82139216D0A4 Q28073970-D96822D8-7B75-4065-A178-C042187F7CA8 Q30234914-EB23CF5C-9B36-4112-9901-9F33E3AD0DA0 Q30244036-92B6FC3F-10CC-4E12-9A5F-7379CDCEDE24 Q30355347-2A97BA0A-B181-44A3-9CB0-2B89AA3A9A70 Q33832709-7D745AAA-B5ED-4D40-8382-57DB06AE8302 Q33865370-D9D8AAC5-F82B-493D-A791-D548502E80A6 Q37060732-2BFCEBBC-D6B7-47ED-9B38-3E100D3FB9C6 Q37084121-38FA2E88-5139-48DA-856E-350D35A8CFE4 Q37141503-B4B5724E-EAB9-4014-9F71-9B1F3AE75D31 Q37270982-5C7C728A-93A0-4BC1-99C8-8BC589CD4D04 Q37317800-6D7FE433-918F-48E1-AFF5-155E8B90904F Q37559783-15E94939-D498-4180-A28F-94FE8DF0851E Q37603441-6B71F91B-71A6-4500-AA3D-D3D4FA502326 Q37624593-6E07A8C5-BFFC-4750-83AB-633600721533 Q37683379-5757C8BA-71F6-465F-8A41-AA17E6019976 Q38672646-F8FDA1BD-685B-4D58-BCBC-AA6C2A143139 Q38701636-E0F14F7C-CBF0-4439-A82F-6FEADD29050B Q38755213-482F62A6-4229-4F37-9ED6-A59AAC22B553 Q38767583-ECFCDB10-4849-4F21-B4DD-7A7A07EC4DD1 Q38801124-2D84C61B-3934-415E-BC10-D113E2E94EA6 Q38850477-9F9B5D3D-B455-4604-9078-ADC82C0D7052 Q38886247-7A945CED-462E-467C-8206-44A31518390D Q38897289-C5C7A6B6-B1D6-452D-942A-E6CE24B5BABA Q38948650-569ECEB5-251B-4A0F-A872-E51913E4B9C9 Q39047646-D96467F0-DBC0-4502-B078-C00238F57E71 Q39097771-AEE0EFDA-0C2D-4BD6-B9B5-EABF8B8B3BAF Q39098284-957A7C52-3372-4BA1-A9E2-B097B1C9BF25 Q39105964-6CEA621B-5C8B-4235-82BC-6B18255D59EE Q39132424-DE7CD760-A57C-4FA3-928C-76BD1992658A Q39135620-3A82D80D-7507-4F42-9B8E-B502C99BCED2 Q39170884-C0809A78-5942-4B50-A794-12FE4FA61641 Q39208298-636039EA-6954-4D14-99D4-0B596F5DB388 Q39264807-15EF1A80-F716-47AA-B63F-6877D817F140 Q39266354-9641959E-AAD5-479E-B310-6B47F3D4378D Q39285841-E1DAB6C9-33A0-4A7F-BB81-3B85F0B69651 Q39400164-A4476F0B-5709-45B7-8EE7-88352FECF6EF Q39601810-0D09CEB6-84DF-4BEF-A96C-F9ACB719638A Q40370775-29AD72D2-7CA4-4CD3-A73C-BF44BB3ECC7C

P2860

Assessment of Minimal Residual Disease in Standard-Risk AML.

http://www.wikidata.org/entity/Q27853325

description

2016 nî lūn-bûn

@nan

2016 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Assessment of Minimal Residual Disease in Standard-Risk AML.

@ast

Assessment of Minimal Residual Disease in Standard-Risk AML.

@en

Assessment of Minimal Residual Disease in Standard-Risk AML.

@nl

type

label

Assessment of Minimal Residual Disease in Standard-Risk AML.

@ast

Assessment of Minimal Residual Disease in Standard-Risk AML.

@en

Assessment of Minimal Residual Disease in Standard-Risk AML.

@nl

prefLabel

Assessment of Minimal Residual Disease in Standard-Risk AML.

@ast

Assessment of Minimal Residual Disease in Standard-Risk AML.

@en

Assessment of Minimal Residual Disease in Standard-Risk AML.

@nl

P1433

Q27853325-9799A20A-D274-4128-836E-CEBF61289C3E

P1476

Q27853325-D01335A6-249D-4BD1-9AD7-4CB73A4C051C

P2093

Q27853325-02C0B9A1-B9DD-47EB-8BFF-44F2BE72FF8C

Q27853325-1DAA3A74-CD84-430D-857E-4732190459C3

Q27853325-27026AF8-83E4-4F92-8157-FD73200C8C0E

Q27853325-2A6910CE-D0CE-4B81-BAF0-B89BA35C1B1D

Q27853325-2B02655C-36DF-44FE-98A2-6539B57C40BC

Q27853325-32D5D0DC-7909-453C-84A5-9AC7542FBB4A

Q27853325-3B53C797-CE7B-4AE1-B46A-7F1C02126CCB

Q27853325-4F65BABF-40C6-4812-8280-43216DCB98A4

Q27853325-5658933C-B649-4EF5-80C8-31D62947C78B

Q27853325-58A207E3-525A-49FD-9D8E-BC91F67F28DB

P304

Q27853325-04E4644C-5207-4745-83D6-27F431B9B166

P31

Q27853325-05F00206-0CD3-49F0-B119-95008D21C33A

P3181

Q27853325-B7732D69-9EFC-49EC-B19B-8958B7198124

P356

Q27853325-2C36B470-5AA7-427C-9190-C2940FF28AEF

P407

Q27853325-4567167F-6AF7-486D-90CB-B9EAC59B81A0

P433

Q27853325-05ED6378-F4FF-427A-8A68-A4928FB6A9F0

P478

Q27853325-DA0DDFE3-9CDC-4943-8643-29032165C032

P50

Q27853325-481A6F95-2BAD-473E-BDCC-7D56E50FE2F1

Q27853325-5B159C8F-E187-4BBA-AA19-63CFDE7B5D79

Q27853325-C90D7B5B-A6C5-47A6-8423-8288ADCB6285

Q27853325-DA2313F5-4B8B-4C98-9A94-85D14F31E3DE

P577

Q27853325-2784C954-A4A9-4682-A056-C674A248332F

P698

Q27853325-D302301B-01A1-4DCD-A516-B0EFA666919A

P3181

P356

P1433

The New England Journal of Medicine

P1476

Assessment of Minimal Residual Disease in Standard-Risk AML.

@en

P2093

Adam Ivey

http://www.w3.org/2001/XMLSchema#string

Alan K Burnett

http://www.w3.org/2001/XMLSchema#string

Amanda Gilkes

http://www.w3.org/2001/XMLSchema#string

Angela Grech

http://www.w3.org/2001/XMLSchema#string

David C Linch

http://www.w3.org/2001/XMLSchema#string

David Grimwade

http://www.w3.org/2001/XMLSchema#string

Ellen Solomon

http://www.w3.org/2001/XMLSchema#string

Frank McCaughan

http://www.w3.org/2001/XMLSchema#string

Hassan Farah

http://www.w3.org/2001/XMLSchema#string

Jelena V Jovanovic

http://www.w3.org/2001/XMLSchema#string

P304

422-33

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2873233

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA1507471

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

374

http://www.w3.org/2001/XMLSchema#string

P50

Michael Simpson

P577

2016-02-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26789727

http://www.w3.org/2001/XMLSchema#string